# A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

> **NCT04657991** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 257 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Binimetinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04657991
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-15
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-08-31
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657991, "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04657991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*